Reply to: "An individualized cirrhosis screening strategy might be more cost-effective in the general population"

J Hepatol. 2022 Dec;77(6):1730. doi: 10.1016/j.jhep.2022.08.006. Epub 2022 Aug 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Liver Cirrhosis* / diagnosis
  • Mass Screening*
  • Research